Serum E-selectin and endothelial cell-specific Molecule-1 levels among people living with HIV on long term ART in Uganda: a pilot cross-sectional study.

"Declarations Ethics approval and consent to participateThe study was approved by the Joint Clinical Research Center (JCRC) Institutional Review Board (JCRC-2021-13) and the Uganda National Council of Science and Technology (UNCST) approval number HS1468ES. Participants included had provided written consent to use their samples in sub studies. All data and samples used in the study were anonymous. We conducted the study in accordance with the ethical guidelines of the 1975 Declaration of Helsinki, principles of good laboratory practice and good clinical practice. Competing interestsThe author reports no conflicts of interest in this work. Competing interests The author reports no conflicts of interest in this work."

"Funding This project was supported by Makerere University Non-Communicable Diseases (MAKNCD) Research Training Program: supported by the Fogarty International Centre of the National Institutes of Health under Award Number D43TW011401. Castelnuovo B is partly supported by Fogarty International Centre of the National Institutes of Health under Award Number D43 TW 009771 (HIV and co-infections). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institute of Health. The ALT cohort is funded by Janssen, the pharmaceutical company of Johnson & Johnson, through a grant to the Academy for Health Innovation, Uganda at Infectious Diseases Institute. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript."